文献速递肿瘤 PET/CT

非小细胞肺癌患者[18F]FDG PET/CT总代谢活性肿瘤体积与总肿瘤负荷的可重复性

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.
PubMed 文献 · EJNMMI Res · 2019-02-07

结果显示,基于多数投票的MV2勾画方法在自动分割中最成功;在90分钟摄取、EARL合规重建和41%最大SUV勾画时,TTB的重复性系数最低(RC=11%);多数情况下,示踪剂摄取时间或重建设置变化对TMATV和TTB可重复性无显著影响,但某些勾画方法之间可重复性存在显著差异。

要点

  • MV2多数投票勾画方法在自动病灶分割中表现最优。
  • TTB在90分钟摄取、EARL重建和41%最大SUV勾画时重复性最佳(RC=11%)。
  • 多数投票勾画可提高可靠性且不损害可重复性,不受采集和重建设置影响。

核心结论

  • 在某些情况下,TMATV和TTB的可重复性显著受病灶勾画方法影响。
  • 采用多数投票方法进行勾画可提高可靠性且不损害可重复性,不受采集和重建设置影响。
  • 使用基于多数投票的肿瘤分割方法,NSCLC患者的TMATV和TTB可被高可靠性和高精度地测量。

研究设计与样本

  • 每天在注射后60和90分钟各采集一次,以评估示踪剂摄取间隔的影响。
  • PET/CT图像按EARL合规设置和PSF建模重建。
  • 使用六种病灶勾画方法:四种直接PET图像衍生勾画和两种基于多数投票的方法(MV2和MV3)。
  • 以三位经验观察者分割共识获得的参考勾画评估各方法准确性。

主要发现

  • 基于与参考勾画的Jaccard指数,MV2勾画方法是自动病灶分割中最成功的方法。
  • 最佳总体重复性见于90分钟摄取扫描、EARL合规重建、以病灶最大SUV的41%勾画的TTB(RC=11%)。
  • 多数情况下,TMATV和TTB的可重复性不受示踪剂摄取时间或重建设置变化的显著影响。
  • 某些病灶勾画方法应用于相同图像时,可重复性存在显著差异。

关键数值与推荐

  • MV2勾画方法基于两个或更多勾画之间的交集,MV3基于三个或更多勾画之间的交集。
  • 最佳总体重复性对应TTB的重复性系数RC=11%,条件为90分钟摄取、EARL合规重建和41%最大SUV勾画。

临床怎么用

  • 在NSCLC患者中测量TMATV和TTB时,建议采用基于多数投票的肿瘤分割方法以提高可靠性和精度。
  • 多数投票勾画方法不受采集和重建设置影响,可在不同条件下保持可重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i.e. intersection between two or more delineations (MV2) and between three or more delineations (MV3). To evaluate the accuracy of those methods, they were compared with a reference delineation obtained from the consensus of the segmentations performed by three experienced observers. Ten NSCLC patients underwent two baseline whole-body [18F]2-Fluoro-2-deoxy-2-D-glucose ([18F]FDG) PET/CT studies on separate days, within 3 days. Two scans were obtained on each day at 60 and 90 min post-injection to assess the influence of tracer uptake interval. PET/CT images were reconstructed following the European Association of Nuclear Medicine Research Ltd. (EARL) compliant settings and with point-spread-function (PSF) modelling. Repeatability between the measurements of each day was determined and the influence of uptake interval, reconstruction settings, and lesion delineation method was assessed using the generalized estimating equations model. RESULTS: Based on the Jaccard index with the reference delineation, the MV2 lesion delineation method was the most successful method for automated lesion segmentation. The best overall repeatability (lowest repeatability coefficient, RC) was found for TTB from 90 min of tracer uptake scans reconstructed with EARL compliant settings and delineated with 41% of lesion's maximum SUV method (RC = 11%). In most cases, TMATV and TTB repeatability were not significantly affected by changes in tracer uptake time or reconstruction settings. However, some lesion delineation methods had significantly different repeatability when applied to the same images. CONCLUSIONS: This study suggests that under some circumstances TMATV and TTB repeatability are significantly affected by the lesion delineation method used. Performing the delineation with a majority vote approach improves reliability and does not hamper repeatability, regardless of acquisition and reconstruction settings. It is therefore concluded that by using a majority vote based tumour segmentation approach, TMATV and TTB in NSCLC patients can be measured with high reliability and precision.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Kolinger GD, Vállez García D, Kramer GM, et al. Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients. EJNMMI Res. 2019. PMID: 30734113. doi:10.1186/s13550-019-0481-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。